Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Gianni, T. Pieńkowski, Y. Im, L. Roman, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. Haba-Rodríguez, S. Im, J. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, P. Valagussa (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.The Lancet. Oncology, 13 1
F Cardoso, LI Veer, J Bogaerts (2016)
Prospective validation of the 70-gene signature in early breast cancerN Engl J Med., 375
S. Swain, J. Baselga, Sung-Bae Kim, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. Ferrero, A. Schneeweiss, S. Heeson, E. Clark, G. Ross, M. Benyunes, J. Cortés (2015)
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.The New England journal of medicine, 372 8
A. Schneeweiss, S. Chia, T. Hickish, Vernon Harvey, A. Eniu, R. Hegg, C. Tausch, J. Seo, Y. Tsai, J. Ratnayake, V. Mcnally, G. Ross, J. Cortés (2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
A. Prat, G. Bianchini, Marlene Thomas, A. Belousov, M. Cheang, A. Koehler, P. Gómez, V. Semiglazov, W. Eiermann, S. Tjulandin, Mikhail Byakhow, B. Bermejo, M. Zambetti, F. Vázquez, L. Gianni, J. Baselga (2014)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH StudyClinical Cancer Research, 20
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
P. Whitworth, L. Stork-Sloots, F. Snoo, P. Richards, Michael Rotkis, J. Beatty, A. Mislowsky, J. Pellicane, B. Nguyen, Laura Lee, C. Nash, M. Gittleman, S. Akbari, P. Beitsch (2014)
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)Annals of Surgical Oncology, 21
O. Krijgsman, P. Roepman, W. Zwart, J. Carroll, S. Tian, F. Snoo, R. Bender, R. Bernards, A. Glas (2012)
A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment responseBreast Cancer Research and Treatment, 133
E. Perez, K. Ballman, Afshin Mashadi-Hossein, Kathleen Tenner, J. Kachergus, N. Norton, B. Necela, Jennifer Carr, S. Ferree, C. Perou, F. Baehner, M. Cheang, A. Thompson (2017)
Intrinsic Subtype and Therapeutic Response Among HER2‐Positive Breast Tumors from the NCCTG (Alliance) N9831 TrialJournal of the National Cancer Institute, 109
WJ Gradishar, BO Anderson, R Balassanian (2016)
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in OncologyJ Natl Compr Cancer Network., 14
F. Cardoso, L. Veer, J. Bogaerts, L. Slaets, G. Viale, S. Delaloge, J. Pierga, E. Brain, S. Causeret, M. Delorenzi, A. Glas, V. Golfinopoulos, T. Goulioti, S. Knox, E. Matos, B. Meulemans, P. Neijenhuis, U. Nitz, R. Passalacqua, P. Ravdin, I. Rubio, M. Saghatchian, T. Smilde, C. Sotiriou, L. Stork, C. Straehle, G. Thomas, A. Thompson, J. Hoeven, P. Vuylsteke, R. Bernards, K. Tryfonidis, E. Rutgers, M. Piccart (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.The New England journal of medicine, 375 8
SM Swain, J Baselga, SB Kim (2015)
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. CLEOPATRA Study GroupN Engl J Med., 372
W. Gradishar, B. Anderson, R. Balassanian, S. Blair, H. Burstein, Amy Cyr, A. Elias, W. Farrar, A. Forero, S. Giordano, M. Goetz, L. Goldstein, C. Hudis, S. Isakoff, P. Marcom, I. Mayer, B. McCormick, M. Moran, Sameer Patel, L. Pierce, E. Reed, K. Salerno, L. Schwartzberg, K. Smith, Mary Smith, H. Soliman, G. Somlo, M. Telli, J. Ward, Dorothy Shead, Rashmi Kumar (2016)
Invasive breast cancer version 1.2016Journal of The National Comprehensive Cancer Network, 14
S. Glück, F. Snoo, J. Peeters, L. Stork-Sloots, G. Somlo (2013)
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapyBreast Cancer Research and Treatment, 139
G. Viale, L. Slaets, F. Snoo, J. Bogaerts, L. Veer, E. Rutgers, M. Piccart-Gebhart, J. Akker, L. Stork-Sloots, L. Russo, P. Dell'Orto, F. Cardoso (2012)
Abstract P4-11-08: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trialCancer Research, 75
Ann Surg Oncol (2017) 24:2539–2546 DOI 10.1245/s10434-017-5863-x OR IG INA L A R TIC L E – BREA S T O NC OLOG Y Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) 1 2 2 3 4 Peter Beitsch, MD , Pat Whitworth, MD , Paul Baron, MD , Michael C. Rotkis, MD , Angela M. Mislowsky, MD , 5 6 7 8 Paul D. Richards, MD , Mary K. Murray, MD , James V. Pellicane, MD , Carrie L. Dul, MD , Charles H. Nash, 9 10 10 11 12 MD , Lisette Stork-Sloots, MSc , Femke de Snoo, MD, PhD , Sarah Untch, BS , and Laura A. Lee, MD 1 2 Targeted Medical Education, Dallas Breast Center, Dallas, TX; Targeted Medical Education, Nashville Breast Center, 3 4 Nashville, TN; Breast & Melanoma Specialists of Charleston, Charleston, SC; Northern Indiana Cancer Research 5 6 Consortium, South Bend, IN; Coastal Carolina Breast Center, Murrells Inlet, SC; Blue Ridge Cancer Care, Roanoke, VA; 7 8 9 Cleveland Clinic Akron General, Akron, OH; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; St. 10 11 John Region, Grosse Pointe Woods,
Annals of Surgical Oncology – Springer Journals
Published: Apr 26, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.